Shell Offers New AI-Powered Applications Through Open AI Energy Initiative
C3 AI (NYSE:AI) and Shell (NYSE:RDS) today announced three new Shell products that will be available through the Open AI Initiative (OAI), an open ecosystem of artificial intelligence (AI)-based solutions for the energy and process industries.
The OAI, launched by C3 AI, Shell, Baker Hughes and Microsoft in February 2021, provides an open framework for energy operators, service & equipment providers, and independent software vendors to offer interoperable solutions, powered by the BHC3 AI Suite and Microsoft Azure. The three new OAI products – Shell Process Optimiser for LNG, Shell Corrosion Advanced Risk Modelling and Analytics, and Shell Autonomous Integrity Recognition – target use cases that will solve key challenges for businesses in the energy industry. By using Shell’s proven domain-specific AI applications built on BHC3’s scalable AI application development platform and SaaS applications, businesses can rapidly move past data discovery and cleaning to application deployment and realization of value in critical business areas.
Details on the new offerings are outlined below:
- Shell Process Optimiser for LNG – The application marries state-of-the-art LNG process engineering and technology with data analytics to enhance asset production by helping asset engineers close the gap between current and optimal production (“gap to potential”) by changing key identified operating conditions as optimization levers. The application integrates sensor information, such as pressure, temperature, and flow rate to calculate the optimum setting using custom-built asset machine learning models. It reveals unknown correlations and sweet spots, and derives the best suitable strategies as optimization know-how. The application, capable of handling operational, economic, and engineering constraints, Shell Process Optimiser for LNG generates actionable insights that can be integrated and brought into the continuous closed loop process control layer for sustained benefits realisation.
- Shell Corrosion Advanced Risk Modelling and Analytics – The application makes use of novel data analytics techniques to predict internal corrosion and erosion to better prioritize and target inspection and maintenance activities. By using a variety of collected site data, and with the help of artificial intelligence, the software provides new insights to predict corrosion and erosion and identify degradation before leaks happen. By using this solution, operators can lower inspection costs and HSSE risk, minimise cost of related leaks, and safely push production to the limit. Additionally, Shell Corrosion Advanced Risk Modelling and Analytics reduces the need for manual, tedious field inspections, resulting in significant time and cost savings.
- Shell Autonomous Integrity Recognition – The application allows inspectors to quickly and easily make use of automated image capture and evaluation to support execution of external integrity inspections. By processing data in the cloud coming from inspections carried out with handheld devices, drones and robots, the solution enables inspectors to objectively evaluate issues, identify items that have been overlooked, reduce the time needed at the desk generating reports, and improve inputs to maintenance planning. Shell Autonomous Integrity Recognition application allows users to identify and classify external corrosion and insulation issues with Machine Vision to reduce leakages. By using this, users can improve the quality, efficiency, and standardization of visual inspections.
These products expand the portfolio of solutions available to OAI subscribers and help accelerate the adoption of enterprise AI in the energy and process industries.
“Previously, there was no framework for Oil and Gas operators to subscribe to proven AI and advanced analytic solutions offered by other operators,” said C3 AI CEO Thomas M. Siebel. “By bringing more solutions built on the BHC3 AI Suite to the OAI, Shell is demonstrating market leadership and establishing the OAI as a one-of-a-kind model of collaboration.”
These applications also broaden the focus areas of the OAI offerings from asset and system reliability to facility and plant optimization and asset integrity, adding to an expanding portfolio of highly differentiated, domain-specific and proven AI applications and modules that are interoperable. These applications can be deployed together to realize business value and create scalable, futureproof reference architectures.
“The products announced today have already been deployed at Shell and have been proven to either create operational efficiencies and savings or generate additional revenue and opportunity,” said Dan Jeavons, Vice President Computational Science and Digital Innovation at Shell. “As more products are added to the growing OAI eco-system, we look forward to working with C3 AI, Baker Hughes, and the other ecosystem partners to build the next-generation platform for the future energy system.”
About C3.ai, Inc.
C3.ai, Inc. (NYSE:AI) is the Enterprise AI application software company that accelerates digital transformation for organizations globally. C3 AI® delivers a family of fully integrated products: C3 AI® Suite, an end-to-end platform for developing, deploying, and operating large-scale AI applications; C3 AI Applications, a portfolio of industry-specific SaaS AI applications; C3 AI CRM, a suite of industry-specific CRM applications designed for AI and machine learning; and C3 AI Ex Machina, a no-code AI solution to apply data science to everyday business problems. The core of the C3 AI offering is an open, model-driven AI architecture that dramatically simplifies data science and application development. Learn more at: www.c3.ai.
About Royal Dutch Shell plc
Royal Dutch Shell plc is incorporated in England and Wales‚ has its headquarters in The Hague and is listed on the London‚ Amsterdam‚ and New York stock exchanges. Shell companies have operations in more than 70 countries and territories with businesses including oil and gas exploration and production; production and marketing of liquefied natural gas and gas to liquids; manufacturing, marketing and shipping of oil products and chemicals and renewable energy projects. For further information, visit www.shell.com. The companies in which Royal Dutch Shell plc directly and indirectly owns investments are separate legal entities. In this document “Shell” is sometimes used for convenience where references are made to Royal Dutch Shell plc and its subsidiaries in general.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211109005579/en/
Contact information
C3 AI Public Relations
Edelman
Lisa Kennedy
415-914-8336
pr@c3.ai
Investor Relations
ir@c3.ai
Shell Media Relations
Laura van Lingen
+31 (0)70 377 8750
Laura.vanLingen@shell.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 13:31:00 EET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 01:49:00 EET | Press release
Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive Officer, Lattice Semiconductor. The annual GSA Awards celebrate the accomplishments of the semiconductor indu
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom